Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease
The Journal of Clinical Hypertension Mar 10, 2018
Bakris GL, et al. - The safety and tolerability of azilsartan medoxomil/chlorthalidone (AZL-M/CLD) versus olmesartan/hydrochlorothiazide (OLM/HCTZ) was determined in hypertensive patients with stage 3 chronic kidney disease. Both AZL-M/CLD and OLM/HCTZ were similar regarding efficacy and tolerability.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
